Bloom Fertility, an INVO Center to grant
three eligible patients a full IVC treatment cycle
SARASOTA, Fla., April 28,
2022 /PRNewswire/ -- INVO Bioscience, Inc.
(NASDAQ: INVO), a commercial-stage fertility company focused
on expanding access to advanced treatment worldwide with its
INVOcell® medical device and the intravaginal culture
("IVC") procedure it enables, today announced that in celebration
of this year's National Infertility Awareness Week ("NIAW"), three
eligible patients will be granted a full IVC treatment cycle free
of charge. The grant program, including patient selection,
will be launched in the coming weeks. NIAW is a movement,
founded in 1989 by RESOLVE, with a mission to empower patients and
help those struggling to build a family.
"We are committed to helping people suffering with infertility
challenges have access to effective and affordable care," stated
Steve Shum, INVO CEO. "This
grant program will benefit selected recipients and is part of our
efforts to build awareness and educate patients on INVOcell as an
effective and available treatment. We believe our INVOcell
technology and the IVC treatment can provide an affordable solution
for patients diagnosed with infertility, and can help address key
industry challenges regarding cost, capacity constraints and access
to care for the large, underserved patient population. We have
three operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with others scheduled to
open in the San Francisco,
Tampa and Kansas City areas later this year. In
collaboration with our partners in Atlanta, we are pleased to offer this grant
program and encourage people with fertility challenges to reach out
to our INVO Center to check eligibility and receive details."
Bloom Fertility, an INVO Center
6 Concourse
Parkway, Suite 250
Atlanta,
GA 30328
Ph
678-597-9933
hellobloomfertility.com
Instagram:
instagram.com/hellobloomfertility
Facebook:
facebook.com/hellobloomfertilityclinic
LinkedIn:
linkedin.com/company/dr-sue-ellen-carpenter-bloom-fertility
About INVO Bioscience
We are a commercial-stage fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our flagship product is INVOcell®, a
revolutionary medical device that allows fertilization and early
embryo development to take place in vivo within the woman's
body. Our primary mission is to implement new medical technologies
aimed at increasing the availability of affordable, high-quality,
patient-centered fertility care. This treatment solution is the
world's first intravaginal culture technique for the incubation of
oocytes and sperm during fertilization and early embryo
development. This technique, designated as "IVC", provides patients
a more natural, intimate, and more affordable experience in
comparison to other ART treatments. The IVC procedure can deliver
comparable results at a fraction of the cost of traditional in
vitro fertilization ("IVF") and is a significantly more effective
treatment than intrauterine insemination ("IUI"). Our
commercialization strategy is focused on the opening of dedicated
"INVO Centers" offering the INVOcell® and IVC procedure
(with three centers in North
America now operational), in addition to continuing to sell
our technology solution into existing fertility clinics. For more
information, please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-celebrates-national-infertility-awareness-week-at-the-invo-center-in-atlanta-georgia-301534965.html
SOURCE INVO Bioscience, Inc.